Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Exelixis, a South San Francisco-based biopharmaceutical firm, and Bristol-Myers Squibb have formed a drug development collaboration covering two Exelixis small molecules for cancer: XL184, a thyroid cancer therapy in Phase III clinical trials, and XL281, a treatment for advanced solid tumors in Phase I trials. Under the agreement, BMS will pay Exelixis $195 million up front for rights to both programs and make additional license payments of $45 million in 2009. The companies have collaborated for nearly a decade.
This article has been sent to the following recipient: